• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨Paget病中的骨肉瘤

Osteosarcoma in Paget's disease of bone.

作者信息

Hansen Marc F, Seton Margaret, Merchant Anand

机构信息

Center for Molecular Medicine, University of Connecticut Health Center, Farmington, Connecticut 06030, USA.

出版信息

J Bone Miner Res. 2006 Dec;21 Suppl 2:P58-63. doi: 10.1359/jbmr.06s211.

DOI:10.1359/jbmr.06s211
PMID:17229010
Abstract

Paget's disease of bone (PDB) is a focal disorder of bone metabolism first described by Sir James Paget in 1876. It is presumed benign in nature and mediated by abnormal osteoclast function. The incidence of osteosarcomas complicating PDB is estimated at <1%. These cancers occur mostly in persons with long-standing, polyostotic disease and affect patients in their seventh decade or when osteosarcoma is remarkably rare in the general population. Epidemiological studies suggest that this late peak of osteosarcomas is absent in regions where Paget's is infrequently reported. Whereas PDB has a predilection for the axial skeleton, skull, femurs, and tibias, pagetic osteosarcoma tend to spare the spine, and are reported more commonly in the pelvis, femur, humerus, and skull. A molecular basis for the association of osteosarcoma with Paget's disease is unclear. These osteosarcomas are osteogenic in origin, consistently arise in sites of pagetic bone, and may present as metachronous, multifocal lesions. On histopathology, the lesions are usually osteoblastic, and the tumor phenotype is sometimes characterized as an exaggerated, chaotic form of the accelerated bone remodeling that characterizes PDB. New insights from the biology of adolescent osteosarcomas, VCP and SQSTM1 mutations now defined in patients with Paget's disease, and emerging evidence that stromal lesions are present in patients with Paget's disease are changing the way we think about the pathogenesis of PDB and the rare complication of pagetic osteosarcomas.

摘要

骨佩吉特病(PDB)是一种骨代谢的局灶性疾病,于1876年由詹姆斯·佩吉特爵士首次描述。其本质上被认为是良性的,由破骨细胞功能异常介导。并发骨佩吉特病的骨肉瘤发病率估计<1%。这些癌症大多发生在患有长期多骨型疾病的患者中,且在一般人群中骨肉瘤极为罕见的第七个十年影响患者。流行病学研究表明,在佩吉特病报告不常见的地区不存在骨肉瘤的这种晚期高峰。虽然骨佩吉特病好发于中轴骨骼、颅骨、股骨和胫骨,但佩吉特骨肉瘤往往不累及脊柱,且在骨盆、股骨、肱骨和颅骨中报告更为常见。骨肉瘤与佩吉特病关联的分子基础尚不清楚。这些骨肉瘤起源于成骨细胞,始终发生在佩吉特骨部位,可能表现为异时性、多灶性病变。在组织病理学上,病变通常为成骨性,肿瘤表型有时被描述为佩吉特病特征性加速骨重塑的一种夸张、混乱形式。青少年骨肉瘤生物学的新见解、现在在佩吉特病患者中确定的VCP和SQSTM1突变,以及佩吉特病患者存在基质病变的新证据,正在改变我们对骨佩吉特病发病机制和佩吉特骨肉瘤罕见并发症的看法。

相似文献

1
Osteosarcoma in Paget's disease of bone.骨Paget病中的骨肉瘤
J Bone Miner Res. 2006 Dec;21 Suppl 2:P58-63. doi: 10.1359/jbmr.06s211.
2
Evidence for increased clinical severity of familial and sporadic Paget's disease of bone in Campania, southern Italy.意大利南部坎帕尼亚地区家族性和散发性骨佩吉特病临床严重程度增加的证据。
J Bone Miner Res. 2006 Dec;21(12):1828-35. doi: 10.1359/jbmr.060822.
3
Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation.畸形性骨炎骨组织及畸形性骨炎肉瘤中的骨基质细胞表达核因子κB受体活化因子配体(RANKL)并支持人破骨细胞形成。
J Pathol. 2006 May;209(1):114-20. doi: 10.1002/path.1953.
4
Somatic mutations in SQSTM1 detected in affected tissues from patients with sporadic Paget's disease of bone.在散发性骨佩吉特病患者的受累组织中检测到的SQSTM1体细胞突变。
J Bone Miner Res. 2009 Mar;24(3):484-94. doi: 10.1359/jbmr.081105.
5
Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma.在家族性和散发性骨佩吉特病及骨肉瘤中对编码核因子κB受体激活剂(RANK)的TNFRSF11A基因进行突变筛查。
Calcif Tissue Int. 2001 Mar;68(3):151-5. doi: 10.1007/s002230001211.
6
Familial incidence of Paget's disease and secondary osteogenic sarcoma. A report of three cases from a single family.佩吉特病和继发性骨肉瘤的家族发病率。来自一个家族的三例报告。
Clin Orthop Relat Res. 1991 Apr(265):306-9.
7
Sarcoma in Paget's disease (11 cases).佩吉特病中的肉瘤(11例)。
Ital J Orthop Traumatol. 1979 Dec;5(3):311-20.
8
Osteoblastic osteosarcoma in monostotic Paget's disease.单发性佩吉特病中的成骨性骨肉瘤
Musculoskelet Surg. 2011 Apr;95(1):37-40. doi: 10.1007/s12306-011-0100-4. Epub 2011 Mar 16.
9
Evaluation of the role of Valosin-containing protein in the pathogenesis of familial and sporadic Paget's disease of bone.含缬酪肽蛋白在家族性和散发性骨Paget病发病机制中的作用评估。
Bone. 2006 Feb;38(2):280-5. doi: 10.1016/j.bone.2005.07.014. Epub 2005 Sep 30.
10
Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone.骨Paget病患者培养的成骨细胞和骨髓基质细胞中的差异基因表达
J Bone Miner Res. 2007 Feb;22(2):298-309. doi: 10.1359/jbmr.061108.

引用本文的文献

1
The osteosarcoma immune microenvironment in progression: PLEK as a prognostic biomarker and therapeutic target.骨肉瘤进展过程中的免疫微环境:PLEK作为一种预后生物标志物和治疗靶点。
Front Immunol. 2025 Aug 15;16:1651858. doi: 10.3389/fimmu.2025.1651858. eCollection 2025.
2
PiRNA hsa_pir_018849 promotes the proliferation and invasion of osteosarcoma cells by regulating the stability of CCN5 mRNA.PiRNA hsa_pir_018849通过调节CCN5 mRNA的稳定性促进骨肉瘤细胞的增殖和侵袭。
J Orthop Surg Res. 2025 Aug 2;20(1):725. doi: 10.1186/s13018-025-06148-6.
3
Evaluation of Indoleamine 2,3-Dioxygenase (IDO) Expression in Osteosarcoma: Insights From a 10-Year Retrospective Cohort.
骨肉瘤中吲哚胺2,3-双加氧酶(IDO)表达的评估:来自一项10年回顾性队列研究的见解
Onco Targets Ther. 2025 Mar 17;18:367-377. doi: 10.2147/OTT.S494899. eCollection 2025.
4
Multimodal Imaging of Osteosarcoma: From First Diagnosis to Radiomics.骨肉瘤的多模态成像:从初次诊断到影像组学
Cancers (Basel). 2025 Feb 10;17(4):599. doi: 10.3390/cancers17040599.
5
Emerging role and function of Hippo-YAP/TAZ signaling pathway in musculoskeletal disorders.Hippo-YAP/TAZ 信号通路在肌肉骨骼疾病中的新兴作用和功能。
Stem Cell Res Ther. 2024 Oct 29;15(1):386. doi: 10.1186/s13287-024-04011-9.
6
Diagnosis and treatment of Paget's disease of bone: position paper from the Italian Society of Osteoporosis, Mineral Metabolism and Skeletal Diseases (SIOMMMS).骨 Paget 病的诊断和治疗:意大利骨质疏松症、矿物质代谢和骨骼疾病学会(SIOMMMS)立场文件。
J Endocrinol Invest. 2024 Jun;47(6):1335-1360. doi: 10.1007/s40618-024-02318-1. Epub 2024 Mar 15.
7
A novel classification predicts prognosis and drug sensitivity in osteosarcoma based on alterations in gene sets.一种基于基因集改变的新型分类方法可预测骨肉瘤的预后和药物敏感性。
Aging (Albany NY). 2024 Feb 28;16(5):4579-4590. doi: 10.18632/aging.205614.
8
Identification of TNFRSF1A as a potential biomarker for osteosarcoma.鉴定 TNFRSF1A 为骨肉瘤的一个潜在生物标志物。
Cancer Biomark. 2024;39(4):299-312. doi: 10.3233/CBM-230086.
9
Descriptive Epidemiology and Survival Rate of Osteosarcoma: The First National Population-Based Study in the Middle East (2008-2014).骨肉瘤的描述性流行病学和生存率:中东地区第一项基于全国人口的研究(2008 - 2014年)
Arch Bone Jt Surg. 2023;11(10):649-657. doi: 10.22038/ABJS.2023.59676.2945.
10
Blockade of IL-10 Signaling Ensures Mifamurtide Efficacy in Metastatic Osteosarcoma.阻断IL-10信号通路可确保米伐木肽对转移性骨肉瘤的疗效。
Cancers (Basel). 2023 Sep 27;15(19):4744. doi: 10.3390/cancers15194744.